• Joe F. Lau
  • Geoffrey D. Barnes
  • Michael B. Streiff


The clinical manifestations of thromboembolic disease were first described by Hippocrates (460–370 BC). In the 17th and 18th centuries, the study of human anatomy in health and disease led to greater understanding of the pathophysiology of thrombotic disease and the first treatments for it. Modern approaches to treatment of arterial and venous thromboembolism emerged in the late 19th and 20th centuries with the identification of acetylsalicylic acid, heparin, and warfarin. The last 50 years has witnessed the development of evidence-based antithrombotic therapy management and targeted therapeutics including glycoprotein IIb/IIIa inhibitors and direct oral anticoagulants directed against thrombin and factor Xa. The ever increasing number of therapeutic agents and procedures for thromboembolic disease presents a challenge for healthcare providers to stay abreast of the latest developments in antithrombotic therapy. We hope this book will be a valuable resource for practitioners caring for patients with thrombotic disease.


Stroke Myocardial infarction Atrial fibrillation Arterial thromboembolism Venous thromboembolism Anticoagulation Treatment Therapy Warfarin Vitamin K antagonist Direct oral anticoagulants Heparin 


  1. 1.
    Pearce JM. Johann Jakob Wepfer (1620-95) and cerebral hemorrhage. J Neurol Neurosurg Psychiatry. 1997;62:387.CrossRefGoogle Scholar
  2. 2.
    de Saint Pathus G. La vie et les Miracles de Saint Louis. Paris: Biblioth eque National de France.1271;1330–50.Google Scholar
  3. 3.
    Galanaud J-P, Laroche J-P, Righini M. The history and historical treatments of deep vein thrombosis. J Thromb Haemost. 2013;11:402–11.CrossRefGoogle Scholar
  4. 4.
    Anning S. The historical aspects. In: Dodd H, Cockett F, editors. The pathology and surgery of the lower limbs. 2nd ed. Edinburgh: Churchill Livingston; 1976. p. 3–17.Google Scholar
  5. 5.
    Hunter H. Observations on the inflammation of the internal coats of veins. Trans Soc Improv Med Chir Knowledge. 1793;1:18–41.Google Scholar
  6. 6.
    Magner L. A history of medicine. New York: Marcel Dekker; 1992. 393 p.Google Scholar
  7. 7.
    Howell H, Holt E. Two new factors in blood coagulation - heparin and pro-antithrombin. Am J Phys. 1918;47:328–41.Google Scholar
  8. 8.
    Murray D, Jacques L, Perrett T, Best C. Heparin and the thrombosis of veins following injury. Surgery. 1937;2:163–87.Google Scholar
  9. 9.
    Wardrop D, Keeling D. The story of the discovery of heparin and warfarin. Br J Haematol. 2008;474:757–63.CrossRefGoogle Scholar
  10. 10.
    Roderick L. The pathology of sweet clover disease in cattle. J Am Vet Med Assoc. 1929;74:314–25.Google Scholar
  11. 11.
    Roderick L. A problem in the coagulation of blood: “sweet clover disease of cattle”. Am J Phys. 1931;96:413–25.Google Scholar
  12. 12.
    Schofield F. The cause of a new disease in cattle stimulating hemorrhagic septicaemia and blackleg. J Am Vet Med Assoc. 1924;64:553–75.Google Scholar
  13. 13.
    Whitlon D, Sadowski J, Suttie J. Mechanisms of coumarin action: significance of vitamin K epoxide reductase inhibition. Biochemistry. 1978;17(8):1371–7.CrossRefGoogle Scholar
  14. 14.
    Stahmann M, Huebner C, Link K. Studies on the hemorrhagic sweet clover disease. J Biol Chem. 1941;138:513–27.Google Scholar
  15. 15.
    Wright I. Experience with anticoagulants. Circulation. 1959;19:110–3.CrossRefGoogle Scholar
  16. 16.
    Prandoni A, Wright I. The anti-coagulants, heparin and the dicoumarin 3,3′ methylene-bis (4-hydroxycoumarin). N Y Acad Med. 1942;18:433.Google Scholar
  17. 17.
    Link K. The discovery of dicoumarol and its sequels. Circulation. 1959;19:97–107.CrossRefGoogle Scholar
  18. 18.
    Makaryus JN, Halperin JL, Lau JF. Oral anticoagulants in the management of venous thromboembolism. Nat Rev Cardiol. 2013;10(7):397–409.CrossRefGoogle Scholar
  19. 19.
    Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuunemann HJ. American college of chest physicians Antithrombotic T, et al. executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):7S–47S.CrossRefGoogle Scholar
  20. 20.
    Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315–52.CrossRefGoogle Scholar
  21. 21.
    Ansell JE. Management of venous thromboembolism: clinical guidance from the Anticoagulation Forum. J Thromb Thrombolysis. 2016;41(1):1–2.CrossRefGoogle Scholar
  22. 22.
    Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galie N, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014;35(43):3033–69, 69a-69k.CrossRefGoogle Scholar
  23. 23.
    Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17(10):1467–507.CrossRefGoogle Scholar
  24. 24.
    Cohen H, Arachchillage DR, Middeldorp S, Beyer-Westendorf J, Abdul-Kadir R. Management of direct oral anticoagulants in women of childbearing potential: guidance from the SSC of the ISTH. J Thromb Haemost. 2016;14(8):1673–6.CrossRefGoogle Scholar
  25. 25.
    Martin K, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost. 2016;14(6):1308–13.CrossRefGoogle Scholar
  26. 26.
    Ruff CT, Ansell JE, Becker RC, Benjamin EJ, Deicicchi DJ, Mark Estes NA, et al. North American Thrombosis Forum, AF action initiative consensus document. Am J Med. 2016;129(5 Suppl):S1–S29.CrossRefGoogle Scholar
  27. 27.
    January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):e199–267.CrossRefGoogle Scholar
  28. 28.
    Task Force Members, Lip GY, Windecker S, Huber K, Kirchhof P, Marin F, Document Reviewers, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J. 2014;35(45):3155–79.CrossRefGoogle Scholar
  29. 29.
    Verma A, Cairns JA, Mitchell LB, Macle L, Stiell IG, Gladstone D, et al. 2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. Can J Cardiol. 2014;30(10):1114–30.CrossRefGoogle Scholar
  30. 30.
    Sticherling C, Marin F, Birnie D, Boriani G, Calkins H, Dan GA, et al. Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS). Europace. 2015;17(8):1197–214.CrossRefGoogle Scholar
  31. 31.
    Heidenreich PA, Solis P, Estes NA 3rd, Fonarow GC, Jurgens CY, Marine JE, et al. 2016 ACC/AHA clinical performance and quality measures for adults with atrial fibrillation or atrial flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. J Am Coll Cardiol. 2016;68(5):525–68.CrossRefGoogle Scholar
  32. 32.
    Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18(11):1609–78.CrossRefGoogle Scholar
  33. 33.
    Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, et al. American Society of Clinical Oncology. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline update 2014. J Clin Oncol. 2015;33(6):654–6.CrossRefGoogle Scholar
  34. 34.
    Streiff MB, Holmstrom B, Ashrani A, Bockenstedt PL, Chesney C, Eby C, et al. Cancer-associated venous thromboembolic disease, version 1.2015. J Natl Compr Cancer Netw. 2015;13(9):1079–95.CrossRefGoogle Scholar
  35. 35.
    Anticoagulation forum centers of excellence. Website
  36. 36.
    Anticoagulation toolkit on anticoagulation forum of excellence. Website
  37. 37.
    Shehab N, Lovegrove MC, Geller AI, Rose KO, Weidle NJ, Budnitz DS. US emergency department visits for outpatient adverse drug events, 2013–2014. JAMA. 2016;316(20):2115–25.CrossRefGoogle Scholar
  38. 38.
    Barnes GD, Nallamothu BK, Sales AE, Froehlich JB. Reimagining anticoagulation clinics in the era of direct oral anticoagulants. Circ Cardiovasc Qual Outcomes. 2016;9(2):182–5.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of CardiologyZucker School of Medicine at Hofstra/Northwell, Northwell HealthManhassetUSA
  2. 2.Department of Internal Medicine, Division of Cardiovascular MedicineFrankel Cardiovascular Center at the University of MichiganAnn ArborUSA
  3. 3.Division of Hematology, Department of MedicineThe Johns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations